Christophe Le Tourneau

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

Ezra E.W. Cohen, Denis Soulières, Christophe Le Tourneau et al. · The Lancet · 2018 · 1.6K citations · Full text

Medicine, Pathology, Head And Neck Cancer +5

Targeting Tumor-Associated Macrophages with Anti-CSF-1R Antibody Reveals a Strategy for Cancer Therapy

Carola H. Ries, Michael A. Cannarile, Sabine Hoves et al. · Cancer Cell · 2014 · 1.3K citations

Cancer Therapy, Tumor Biology, Tumor-associated Macrophages +12

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial

Christophe Le Tourneau, Jean-Pierre Delord, Anthony Gonçalvès et al. · The Lancet Oncology · 2015 · 1.1K citations

Advanced Cancer, Drug Targeting, Oncology +12

Genomic characterization of metastatic breast cancers

François Bertucci, Charlotte K.Y. Ng, Anne Patsouris et al. · Nature · 2019 · 706 citations

Breast Oncology, Oncology, Medicine +5

Hyperprogression during anti-PD-1/PD-L1 therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Esma Saâda-Bouzid, Cécile Defaucheux, Andy Karabajakian et al. · Annals of Oncology · 2017 · 596 citations

Oncology, Neoadjuvant Therapy, Anti-pd-1/pd-l1 Therapy +6